Glucocerebrosidase gene therapy - Sanofi Genzyme

Drug Profile

Glucocerebrosidase gene therapy - Sanofi Genzyme

Alternative Names: Gaucher's disease gene therapy - Genzyme

Latest Information Update: 21 Dec 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nonindustrial source
  • Developer Sanofi Genzyme
  • Class Gene therapies
  • Mechanism of Action Gene transference; Glucosylceramidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Gaucher's disease

Most Recent Events

  • 22 Jun 2005 Preclinical data presented at the 8th Annual Meeting of the American Society of Gene Therapy (ASGT-2005) have been added to the Metabolic disorders pharmacodynamics section
  • 29 Jul 2003 Genzyme General, Genzyme Biosurgery and Genzyme Molecular Oncology are now called Genzyme Corporation
  • 25 Jun 2003 Preclinical trials in Gaucher's disease in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top